Tempus AI Surges 1.49% on $800M Trading Volume Ranks 139th in U.S. Liquidity

Tempus AI (TEM) surged 1.49% on October 2, with a trading volume of $800 million, ranking 139th among U.S. stocks by liquidity. The biotech firm's shares gained momentum amid renewed investor focus on AI-driven diagnostics and regulatory progress in clinical trial frameworks.

Recent developments highlighted Tempus' strategic partnerships with academic institutions to expand its genomic database, while quarterly reports indicated steady revenue growth from enterprise software contracts. Analysts noted that the stock's performance correlated with broader market optimism toward healthcare technology innovation, though volume levels remained below 90-day averages.

Backtesting parameters for evaluating Tempus' historical returns require clarification on key execution variables: universe scope (US equities vs. ADRs/ETFs), pricing methodology (open-to-close vs. close-to-close), transaction cost assumptions (e.g., 2 bps per trade), capital allocation strategy (equal weighting across 500 stocks), and data vendor preferences for OHLC prices and volume metrics. These factors will directly influence the accuracy of performance simulations from January 1, 2022, to the present.